Float Short %

8.33

Margin Of Safety %

Put/Call OI Ratio

0.1

EPS Next Q Diff

0.1

EPS Last/This Y

0.77

EPS This/Next Y

0.56

Price

13.88

Target Price

17.6

Analyst Recom

1.6

Performance Q

25.36

Relative Volume

0.48

Beta

0.99

Ticker: ENTA

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-09	ENTA	14.65	0.37	0.75	2997
2025-12-10	ENTA	14.39	0.37	1.50	2999
2025-12-11	ENTA	14.16	0.37	0.17	3000
2025-12-12	ENTA	14.75	0.37	2.00	3004
2025-12-15	ENTA	14.89	0.37	999.99	3007
2025-12-16	ENTA	14.85	0.37	0.00	3010
2025-12-17	ENTA	14.24	0.38	3.50	2990
2025-12-18	ENTA	14.55	0.38	0.00	3004
2025-12-19	ENTA	15.4	0.38	0.05	3033
2025-12-22	ENTA	16.23	0.08	1.50	2324
2025-12-23	ENTA	15.72	0.09	0.00	2331
2025-12-26	ENTA	16.86	0.09	0.00	2387
2025-12-29	ENTA	16.48	0.08	0.00	2429
2025-12-30	ENTA	15.91	0.08	0.00	2428
2025-12-31	ENTA	15.77	0.08	0.00	2428
2026-01-02	ENTA	14.4	0.08	1.62	2426
2026-01-05	ENTA	13.93	0.10	0.00	2511
2026-01-06	ENTA	13.6	0.10	0.01	2541
2026-01-07	ENTA	13.9	0.10	0.00	2613
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-09	ENTA	14.64	49.1	-	-2.30
2025-12-10	ENTA	14.64	49.1	-	-2.30
2025-12-11	ENTA	14.14	49.1	-	-2.30
2025-12-12	ENTA	14.75	49.1	-	-2.30
2025-12-15	ENTA	14.87	49.1	-	-2.30
2025-12-16	ENTA	14.87	49.1	-	-2.30
2025-12-17	ENTA	14.24	49.1	-	-2.30
2025-12-18	ENTA	14.53	49.1	-	-3.07
2025-12-19	ENTA	15.43	23.1	-	-3.07
2025-12-22	ENTA	16.21	23.1	-	-3.07
2025-12-23	ENTA	15.77	23.1	-	-3.07
2025-12-26	ENTA	16.85	23.1	-	-3.07
2025-12-29	ENTA	16.44	23.1	-	-3.07
2025-12-30	ENTA	15.91	23.1	-	-3.07
2025-12-31	ENTA	15.77	23.1	-	-3.07
2026-01-02	ENTA	14.41	23.1	-	-3.07
2026-01-05	ENTA	13.93	23.1	-	-3.07
2026-01-06	ENTA	13.56	23.1	-	-3.07
2026-01-07	ENTA	13.88	23.1	-	-3.07
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-09	ENTA	-0.85	15.49	10.25
2025-12-10	ENTA	-0.85	15.49	9.07
2025-12-11	ENTA	-0.85	15.49	9.07
2025-12-12	ENTA	-0.85	15.49	9.07
2025-12-15	ENTA	-0.85	15.46	9.05
2025-12-16	ENTA	-0.88	15.46	9.05
2025-12-17	ENTA	-0.88	15.46	9.05
2025-12-18	ENTA	-0.88	15.46	9.05
2025-12-19	ENTA	-0.88	15.46	9.05
2025-12-22	ENTA	-0.88	15.46	9.05
2025-12-23	ENTA	-0.88	15.46	9.05
2025-12-26	ENTA	-0.88	15.46	8.33
2025-12-29	ENTA	-0.88	15.46	8.33
2025-12-30	ENTA	-0.88	15.46	8.33
2025-12-31	ENTA	-0.88	15.46	8.33
2026-01-02	ENTA	-0.88	15.46	8.33
2026-01-05	ENTA	-0.88	15.46	8.33
2026-01-06	ENTA	-0.88	15.46	8.33
2026-01-07	ENTA	-0.88	15.46	8.33
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.87

Avg. EPS Est. Current Quarter

-0.81

Avg. EPS Est. Next Quarter

-0.77

Insider Transactions

-0.88

Institutional Transactions

15.46

Beta

0.99

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

86.4

Max Drawdown 5-Year %

-95.6

Target Price

17.6

P/E

Forward P/E

PEG

P/S

6.14

P/B

4.59

P/Free Cash Flow

EPS

-3.84

Average EPS Est. Cur. Y

-3.07

EPS Next Y. (Est.)

-2.5

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-125.36

Relative Volume

0.48

Return on Equity vs Sector %

-153.6

Return on Equity vs Industry %

-138.5

EPS 1 7Days Diff

-0.8

EPS 1 30Days Diff

0.08

EBIT Estimation

Enanta Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 120

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

stock quote shares ENTA – Enanta Pharmaceuticals Inc Stock Price stock today

news today ENTA – Enanta Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch ENTA – Enanta Pharmaceuticals Inc yahoo finance google finance

stock history ENTA – Enanta Pharmaceuticals Inc invest stock market

stock prices ENTA premarket after hours

ticker ENTA fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ENTA

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y